Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Background Since 2009, IPF patients across Europe are recruited into the eurIPFreg,
providing epidemiological data and biomaterials for translational research. Methods The …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background Published data for the epidemiology of idiopathic pulmonary fibrosis in the USA
are scarce. We sought to estimate the incidence, prevalence, and mortality risk of idiopathic …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an
overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication …

Idiopathic pulmonary fibrosis (IPF) is featured with inflammation and extensive lung
remodeling caused by overloaded deposition of extracellular matrix. Scutellarin is the major …

Background There is an urgent need for biomarkers to better stratify patients with idiopathic
pulmonary fibrosis by risk for lung transplantation allocation who have the same clinical …